Fatty Liver Disease Gets a New Name and Definition - Impact on Diagnosis and Updates in Treatment/Care
Alina M. Allen, M.D.

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Describe the new nomenclature and definition of the disease previously known as NAFLD
• Recognize patients who are at risk for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• Employ risk stratification algorithms to determine the need for hepatology referral
• Use updated strategies for the treatment and care of patients with MASLD

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.